1,000+ Opportunities
Find the right grant
Search federal, foundation, and corporate grants with AI — or browse by agency, topic, and state.
Advancing Real-World Effectiveness Evidence for Rapid-Acting Psychotropic Interventional Drugs (RAPIDs) is sponsored by National Institutes of Health. Advancing Real-World Effectiveness Evidence for Rapid-Acting Psychotropic Interventional Drugs (RAPIDs) is a forecasted funding opportunity on Grants. gov from National Institutes of Health.
Fiscal Year: 2027. Assistance Listing Number(s): 93. 242.
<p>The National Institute of Mental Health (NIMH) intends to publish a Notice of Funding Opportunity (NOFO) to support the development of a research network to study rapid-acting psychotropic interventional drugs (RAPIDs), such as ketamine, esketamine, psilocybin, and other emerging treatments for serious mental illnesses.
</p><p>Preliminary studies suggest that RAPIDs can produce clinically meaningful improvements in mental health outcomes, in some cases following a single dose. However, i...
Get a weekly digest of new grants like this
A free weekly digest of new foundation and federal funding opportunities as they're added to Granted. Unsubscribe anytime.
Or search similar grants →According to the current listing, eligibility includes: Eligible applicant types: County governments, Private institutions of higher education, Independent school districts, State governments, Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education, City or township governments, Others (see text field entitled "Additional Information on Eligibility" for clarification), Small businesses, Public and State controlled institutions of higher education, Public housing authorities/Indian housing authorities, Native American tribal organizations (other than Federally recognized tribal governments), Special district governments, Native American tribal governments (Federally recognized), Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education, For profit organizations other than small businesses. Confirm the full requirements in the official notice before applying.
Yes — Advancing Real-World Effectiveness Evidence for Rapid-Acting Psychotropic Interventional Drugs (RAPIDs) is offered by National Institutes of Health and this listing comes from Grants.gov, an official U.S. federal source. Federal applications generally require registrations (for example SAM.gov or an agency submission portal), so allow extra lead time.
Start from the official opportunity page linked in this listing — it carries the sponsor's submission instructions.
PA-27-037 consolidates the Predoctoral to Postdoctoral Transition Award into a single parent announcement across 20 NIH components, with the next deadline December 8, 2026. The eligibility gate is not the science — it is a mandatory change of institution and mentor between the F99 and K00 phases.
Read articleA draft executive order would have put OMB Director Russell Vought on a commission with final say over NIH awards after peer review. Sen. Collins killed it by pointing at a provision Congress already passed. Here is what the episode teaches applicants about the December 11 cliff.
Read articlePA-27-034, PA-27-035 and PA-27-036 replace the institute-specific R25 announcements that research education programs have been built around for a decade. NCI, NIDA and NIGMS have already expired theirs early. Here is what the consolidation actually changes: an 8% indirect cost ceiling, a US-citizens-and-permanent-residents participant rule, a cooperative agreement variant that only exists on one of the three, and no clinical-trial-allowed companion anywhere.
Read article